Advertisement

Resistance of Herpesviruses to Antiviral Agents

  • William L. Drew
  • Jocelyne Piret
  • Guy Boivin
Chapter
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)

Abstract

Acyclovir is the prototype of a series of antivirals which are effective against herpesviruses. However, resistance to this class of drugs can occur and is being seen mainly in immunocompromised patients with herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Clinical use of intravenous ganciclovir began in 1984 for the treatment of life-threatening and sight-threatening human cytomegalovirus (HCMV) infections in immunocompromised patients. A few years later, emergence of ganciclovir-resistant HCMV strains was reported in AIDS patients with HCMV retinitis and, thereafter, in organ or bone marrow transplant recipients. Foscarnet and cidofovir became available subsequently, and resistance to these agents has also been described.

In this chapter, we review the available antiviral drugs for the prevention and treatment of HCMV, HSV, and VZV infections, the methods for detecting antiviral resistance, the clinical significance of infections caused by drug-resistant strains, and their management.

Notes

Acknowledgments

This study was supported by a Foundation Grant from the Canadian Institutes of Health Research (grant no. 148361 to G.B.). G.B. is the holder of the Canada research chair on emerging viruses and antiviral resistance.

References

  1. 1.
    Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immunocompromised patients. Herpes. 2007;14:32–6.PubMedGoogle Scholar
  2. 2.
    Andrei G, Fiten P, Froeyen M, De Clercq E, Opdenakker G, Snoeck R. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther. 2007;12:719–32.PubMedGoogle Scholar
  3. 3.
    Andrei G, Topalis D, Fiten P, McGuigan C, Balzarini J, Opdenakker G, et al. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol. 2012;86:2641–52.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Andrei G, Georgala A, Topalis D, Fiten P, Aoun M, Opdenakker G, et al. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J Infect Dis. 2013;207:1295–305.PubMedCrossRefGoogle Scholar
  5. 5.
    Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis. 2013;26:551–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46:840.PubMedCrossRefGoogle Scholar
  8. 8.
    Bacon TH, Boon RJ, Schultz M, Hodges-Savola C. Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis. Antimicrob Agents Chemother. 2002;46:3042–4.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114–28.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol. 1995;69:796–800.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Baldanti F, Underwood MR, Stanat SC, Biron KK, Chou S, Sarasini A, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol. 1996;70:1390–5.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, et al. The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother. 1998;42:444–6.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Baldanti F, Michel D, Simoncini L, Heuschmid M, Zimmermann A, Minisini R, et al. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antivir Res. 2002;54:59–67.PubMedCrossRefGoogle Scholar
  14. 14.
    Baldanti F, Lilleri D, Campanini G, Comolli G, Ridolfo AL, Rusconi S, et al. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. J Antimicrob Chemother. 2004;53:536–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999;340:1255–68.PubMedCrossRefGoogle Scholar
  16. 16.
    Bendel AE, Gross TG, Woods WG, Edelman CK, Balfour HH Jr. Failure of foscarnet in disseminated herpes zoster. Lancet. 1993;341:1342.PubMedCrossRefGoogle Scholar
  17. 17.
    Benz C, Holz G, Michel D, Awerkiew S, Dries V, Stippel D, et al. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient. Transplantation. 2003;75:724–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Besecker MI, Furness CL, Coen DM, Griffiths A. Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia. J Virol. 2007;81:8356–60.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Bestman-Smith J, Boivin G. Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. J Med Virol. 2002;67:88–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol. 2003;77:7820–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. 2002;21:1274–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985;82:2473–7.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA, Davis MG, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46:2365–72.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev. 1998;11:533–54.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother. 1993;37:357–9.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994;170:68–75.PubMedCrossRefGoogle Scholar
  28. 28.
    Boivin G, Chou S, Quirk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis. 1996;173:523–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis. 2001;184:1598–602.PubMedCrossRefGoogle Scholar
  30. 30.
    Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004;189:1615–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol. 2005;77:425–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis. 2005;7:166–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Boon RJ, Bacon TH, Robey HL, Coleman TJ, Connolly A, Crosson P, et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey. J Antimicrob Chemother. 2000;46:324–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis. 1998;27:1525–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Brink AA, van Gelder M, Wolffs PF, Bruggeman CA, van Loo IH. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis. 2011;52:982–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Brunnemann AK, Bohn-Wippert K, Zell R, Henke A, Walther M, Braum O, et al. Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate. Antimicrob Agents Chemother. 2015;59:2726–34.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Brunnemann AK, Liermann K, Deinhardt-Emmer S, Maschkowitz G, Pohlmann A, Sodeik B, et al. Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility. Sci Rep. 2016;6:29903.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Bryan CJ, Prichard MN, Daily S, Jefferson G, Hartline C, Cassady KA, et al. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J. 2008;27:946–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Burrel S, Bonnafous P, Hubacek P, Agut H, Boutolleau D. Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity. Antivir Res. 2012;96:386–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Burrel S, Aime C, Hermet L, Ait-Arkoub Z, Agut H, Boutolleau D. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Antivir Res. 2013;100:365–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Burrel S, Boutolleau D, Azar G, Doan S, Deback C, Cochereau I, et al. Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis. J Clin Virol. 2013;58:321–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis. 2000;181:2055–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med. 1989;320:297–300.PubMedCrossRefGoogle Scholar
  44. 44.
    Chatis PA, Crumpacker CS. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology. 1991;180:793–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Chen H, Beardsley GP, Coen DM. Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc Natl Acad Sci U S A. 2014;111:17462–7.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Chen Y, Scieux C, Garrait V, Socie G, Rocha V, Molina JM, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 2000;31:927–35.PubMedCrossRefGoogle Scholar
  48. 48.
    Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21:311–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis. 1995;171:576–83.PubMedCrossRefGoogle Scholar
  50. 50.
    Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis. 1997;176:786–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Chou S, Marousek G, Parenti DM, Gordon SM, LaVoy AG, Ross JG, et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis. 1998;178:526–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob Agents Chemother. 1999;43:1500–2.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Chou S, Meichsner CL. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob Agents Chemother. 2000;44:183–5.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis. 2002;185:162–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis. 2003;188:32–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother. 2005;49:2710–5.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Chou S, Hakki M, Villano S. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antivir Res. 2012;95:88–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Chou S, Ercolani RJ, Marousek G, Bowlin TL. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother. 2013;57:3375–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 1991;41:104–29.PubMedCrossRefGoogle Scholar
  60. 60.
    Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, et al. Survey of resistance of herpes simplex virus to acyclovir in Northwest England. Antimicrob Agents Chemother. 1998;42:868–72.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol. 1996;50:1502–10.PubMedGoogle Scholar
  62. 62.
    Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol. 1998;72:5927–36.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology. 1998;248:382–93.PubMedCrossRefGoogle Scholar
  64. 64.
    Collins P, Larder BA, Oliver NM, Kemp S, Smith IW, Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol. 1989;70:375–82.PubMedCrossRefGoogle Scholar
  65. 65.
    Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol. 1993;(Suppl 1):58–66.CrossRefGoogle Scholar
  66. 66.
    Crassard N, Souillet AL, Morfin F, Thouvenot D, Claudy A, Bertrand Y. Acyclovir-resistant varicella infection with atypical lesions in a non-HIV leukemic infant. Acta Paediatr. 2000;89:1497–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Dambrosi S, Martin M, Yim K, Miles B, Canas J, Sergerie Y, et al. Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models. J Med Virol. 2010;82:1000.PubMedCrossRefGoogle Scholar
  68. 68.
    Dankner WM, Scholl D, Stanat SC, Martin M, Sonke RL, Spector SA. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J Virol Methods. 1990;28:293–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol. 2004;42:242–9.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Darby G, Larder BA, Inglis MM. Evidence that the ‘active center’ of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol. 1986;67:753–8.CrossRefGoogle Scholar
  71. 71.
    De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol. 2004;68:2301–15.PubMedCrossRefGoogle Scholar
  72. 72.
    DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:1009–16.PubMedCrossRefGoogle Scholar
  73. 73.
    Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991;163:716–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:289–91.PubMedCrossRefGoogle Scholar
  75. 75.
    Drew WL, Stempien MJ, Andrews J, Shadman A, Tan SJ, Miner R, et al. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis. 1999;179:1352–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Drew WL, Paya CV, Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant. 2001;1:307–12.PubMedCrossRefGoogle Scholar
  77. 77.
    Drew WL. Cytomegalovirus disease in highly active antiretroviral therapy era. Curr Infect Dis Rep. 2003;5:257–65.PubMedCrossRefGoogle Scholar
  78. 78.
    Drew WL, Liu C. Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus. Clin Transpl. 2012;26:949–52.CrossRefGoogle Scholar
  79. 79.
    Drouot E, Piret J, Boivin G. Novel method based on "en passant" mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J Clin Microbiol. 2013;51:3216–24.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis. 2008;198:659–63.PubMedCrossRefGoogle Scholar
  81. 81.
    Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood. 2000;96:3286–9.PubMedGoogle Scholar
  82. 82.
    Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transpl. 2008;22:162–70.CrossRefGoogle Scholar
  83. 83.
    Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA. 1990;263:1662–4.PubMedCrossRefGoogle Scholar
  84. 84.
    Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH Jr. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 1990;112:416–22.PubMedCrossRefGoogle Scholar
  85. 85.
    Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis. 2007;196:266–70.PubMedCrossRefGoogle Scholar
  86. 86.
    Erice A, Gil-Roda C, Perez JL, Balfour HH Jr, Sannerud KJ, Hanson MN, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis. 1997;175:1087–92.PubMedCrossRefGoogle Scholar
  87. 87.
    Erice A, Borrell N, Li W, Miller WJ, Balfour HH Jr. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis. 1998;178:531–4.PubMedCrossRefGoogle Scholar
  88. 88.
    Erlich KS, Jacobson MA, Koehler JE, Follansbee SE, Drennan DP, Gooze L, et al. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med. 1989;110:710–3.PubMedCrossRefGoogle Scholar
  89. 89.
    Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989;320:293–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Field HJ, Vere Hodge RA. Recent developments in anti-herpesvirus drugs. Br Med Bull. 2013;106:213–49.PubMedCrossRefGoogle Scholar
  91. 91.
    Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir study group. J Infect Dis. 1994;169:1338–41.PubMedCrossRefGoogle Scholar
  92. 92.
    Fillet AM, Visse B, Caumes E, Dumont B, Gentilini M, Huraux JM. Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis. 1995;21:1348–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Fillet AM, Dumont B, Caumes E, Visse B, Agut H, Bricaire F, et al. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Virol. 1998;55:250–4.PubMedCrossRefGoogle Scholar
  94. 94.
    Fillet AM, Auray L, Alain S, Gourlain K, Imbert BM, Najioullah F, et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother. 2004;48:1865–8.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 2014;58:785–803.PubMedCrossRefGoogle Scholar
  96. 96.
    Frangoul H, Wills M, Crossno C, Engel M, Domm J. Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant. 2007;11:942–4.PubMedCrossRefGoogle Scholar
  97. 97.
    Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno JS, et al. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antivir Res. 2014;111:36–41.PubMedCrossRefGoogle Scholar
  98. 98.
    Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978;253:8721–7.PubMedGoogle Scholar
  99. 99.
    Gaudreau A, Hill E, Balfour HH Jr, Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis. 1998;178:297–303.PubMedCrossRefGoogle Scholar
  100. 100.
    Gerna G, Baldanti F, Zavattoni M, Sarasini A, Percivalle E, Revello MG. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antivir Res. 1992;19:333–45.PubMedCrossRefGoogle Scholar
  101. 101.
    Gerna G, Sarasini A, Lilleri D, Percivalle E, Torsellini M, Baldanti F, et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis. 2003;188:1639–47.PubMedCrossRefGoogle Scholar
  102. 102.
    Gilbert C, Roy J, Belanger R, Delage R, Beliveau C, Demers C, et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother. 2001;45:3669–71.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat. 2002;5:88–114.PubMedCrossRefGoogle Scholar
  104. 104.
    Gilbert C, Boivin G. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS. 2003;17:337–41.PubMedCrossRefGoogle Scholar
  105. 105.
    Gilbert C, Boivin G. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob Agents Chemother. 2005;49:4860–6.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother. 2005;49:873–83.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884–93.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58:610–3.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Gueudry J, Boutolleau D, Gueudin M, Burrel S, Miri A, Bodaghi B, et al. Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient. J Clin Virol. 2013;58:318–20.PubMedCrossRefGoogle Scholar
  110. 110.
    Gupta R, Hill EL, McClernon D, Davis G, Selke S, Corey L, et al. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J Infect Dis. 2005;192:1102–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis. 2003;187:139–43.PubMedCrossRefGoogle Scholar
  112. 112.
    Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother. 1995;39:1204.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Hew K, Dahlroth SL, Veerappan S, Pan LX, Cornvik T, Nordlund P. Structure of the varicella zoster virus thymidylate synthase establishes functional and structural similarities as the human enzyme and potentiates itself as a target of brivudine. PLoS One. 2015;10:e0143947.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1991;35:2322–8.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Hostetler KY. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Virus. 2010;2:2213–25.CrossRefGoogle Scholar
  116. 116.
    Hu H, Jabs DA, Forman MS, Martin BK, Dunn JP, Weinberg DV, et al. Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J Infect Dis. 2002;185:861–7.PubMedCrossRefGoogle Scholar
  117. 117.
    Huang L, Ishii KK, Zuccola H, Gehring AM, Hwang CB, Hogle J, et al. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases. Proc Natl Acad Sci U S A. 1999;96:447–52.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant. 2005;5:1462–8.PubMedCrossRefGoogle Scholar
  119. 119.
    Hwang CB, Ruffner KL, Coen DM. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol. 1992;66:1774–6.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis. 1998;177:770.PubMedCrossRefGoogle Scholar
  121. 121.
    Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42:2240–4.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2001;183:333–7.PubMedCrossRefGoogle Scholar
  123. 123.
    Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, et al. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am J Ophthalmol. 2001;132:700–10.PubMedCrossRefGoogle Scholar
  124. 124.
    Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;112:187–91.PubMedCrossRefGoogle Scholar
  125. 125.
    James SH, Prichard MN. A possible pitfall in acyclovir prophylaxis for recurrent herpetic keratitis? J Infect Dis. 2013;208:1353–5.PubMedCrossRefGoogle Scholar
  126. 126.
    Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K, et al. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. J Acquir Immune Defic Syndr. 1999;21:301–6.PubMedCrossRefGoogle Scholar
  127. 127.
    Kamiyama T, Kurokawa M, Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol. 2001;82:2761–5.PubMedCrossRefGoogle Scholar
  128. 128.
    Karamitros T, Harrison I, Piorkowska R, Katzourakis A, Magiorkinis G, Mbisa JL. De novo assembly of human herpes virus type 1 (HHV-1) genome, mining of non-canonical structures and detection of novel drug-resistance mutations using short- and long-read next generation sequencing technologies. PLoS One. 2016;11:e0157600.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11:1079–84.PubMedCrossRefGoogle Scholar
  130. 130.
    Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DR, et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:147–52.PubMedCrossRefGoogle Scholar
  131. 131.
    Kesson AM, Zeng F, Cunningham AL, Rawlinson WD. The use of flow cytometry to detect antiviral resistance in human cytomegalovirus. J Virol Methods. 1998;71:177–86.PubMedCrossRefGoogle Scholar
  132. 132.
    Kim JH, Schaenman JM, Ho DY, Brown JM. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol Blood Marrow Transplant. 2011;17:259–64.PubMedCrossRefGoogle Scholar
  133. 133.
    Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med. 1993;329:1777–82.PubMedCrossRefGoogle Scholar
  134. 134.
    Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–60.CrossRefGoogle Scholar
  135. 135.
    Krawczyk A, Arndt MA, Grosse-Hovest L, Weichert W, Giebel B, Dittmer U, et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A. 2013;110:6760–5.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Kriesel JD, Spruance SL, Prichard M, Parker JN, Kern ER. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis. 2005;192:156–61.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 1999;68:1272–9.PubMedCrossRefGoogle Scholar
  138. 138.
    Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997;176:892–8.PubMedCrossRefGoogle Scholar
  139. 139.
    Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 2000;44:688–92.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Langston AA, Redei I, Caliendo AM, Somani J, Hutcherson D, Lonial S, et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood. 2002;99:1085–8.PubMedCrossRefGoogle Scholar
  141. 141.
    Lascaux AS, Caumes E, Deback C, Melica G, Challine D, Agut H, et al. Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. J Med Virol. 2012;84:194–7.PubMedCrossRefGoogle Scholar
  142. 142.
    Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis. 2003;188:954–9.PubMedCrossRefGoogle Scholar
  143. 143.
    Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis. 2004;39:S248–57.PubMedCrossRefGoogle Scholar
  144. 144.
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–9.PubMedCrossRefGoogle Scholar
  145. 145.
    Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866–72.PubMedCrossRefGoogle Scholar
  146. 146.
    Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation. 2006;81:1645–52.PubMedCrossRefGoogle Scholar
  147. 147.
    Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54:1290–7.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Liu W, Kuppermann BD, Martin DF, Wolitz RA, Margolis TP. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. J Infect Dis. 1998;177:1176–81.PubMedCrossRefGoogle Scholar
  149. 149.
    Lolis MS, Gonzalez L, Cohen PJ, Schwartz RA. Drug-resistant herpes simplex virus in HIV infected patients. Acta Dermatovenerol Croat. 2008;16:204–8.PubMedGoogle Scholar
  150. 150.
    LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis. 1998;26:512–3.PubMedCrossRefGoogle Scholar
  151. 151.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340:1462–70.PubMedCrossRefGoogle Scholar
  152. 152.
    Lurain NS, Weinberg A, Crumpacker CS, Chou S, Adult AIDS Clinical Trials Group-CMV Laboratories. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother. 2001;45:2775–80.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Lurain NS, Bhorade SM, Pursell KJ, Avery RK, Yeldandi VV, Isada CM, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis. 2002;186:760–8.PubMedCrossRefGoogle Scholar
  154. 154.
    Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689–712.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Malartre N, Boulieu R, Falah N, Cortay JC, Lina B, Morfin F, et al. Effects of mutations on herpes simplex virus 1 thymidine kinase functionality: an in vitro assay based on detection of monophosphate forms of acyclovir and thymidine using HPLC/DAD. Antivir Res. 2012;95:224–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Martin JL, Ellis MN, Keller PM, Biron KK, Lehrman SN, Barry DW, et al. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrob Agents Chemother. 1985;28:181–7.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227–36.PubMedCrossRefGoogle Scholar
  158. 158.
    McSharry JM, Lurain NS, Drusano GL, Landay A, Manischewitz J, Nokta M, et al. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. J Clin Microbiol. 1998;36:958–64.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Mertz GJ, Jones CC, Mills J, Fife KH, Lemon SM, Stapleton JT, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA. 1988;260:201–6.PubMedCrossRefGoogle Scholar
  160. 160.
    Michel D, Hohn S, Haller T, Jun D, Mertens T. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J Med Virol. 2001;65:70–6.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother. 1999;43:2412–6.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis. 2000;182:290–3.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26:29–37.PubMedCrossRefGoogle Scholar
  164. 164.
    Mousavi-Jazi M, Schloss L, Drew WL, Linde A, Miner RC, Harmenberg J, et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol. 2001;23:1–15.PubMedCrossRefGoogle Scholar
  165. 165.
    Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis. 2002;34:1337–41.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Nichols WG, Boeckh M. Cytomegalovirus infections. Curr Treat Opt Infect Dis. 2001;3:78–91.Google Scholar
  167. 167.
    Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–74.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Nichols WG, Boeckh M, Carter RA, Wald A, Corey L. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. J Infect Dis. 2003;187:801–8.PubMedCrossRefGoogle Scholar
  169. 169.
    Nugier F, Colin JN, Aymard M, Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol. 1992;36:1–12.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Pan D, Kaye SB, Hopkins M, Kirwan R, Hart IJ, Coen DM. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J Infect Dis. 2014;209:345–9.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Baek S, et al. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother. 2012;67:1486–92.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–20.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis. 2002;185:854–60.PubMedCrossRefGoogle Scholar
  174. 174.
    Perrier M, Desire N, Deback C, Agut H, Boutolleau D, Burrel S. Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals. J Virol Methods. 2016;233:10–4.PubMedCrossRefGoogle Scholar
  175. 175.
    Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811–5.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55:459–72.PubMedCrossRefGoogle Scholar
  177. 177.
    Piret J, Boivin G. Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol. 2014;24:186–218.PubMedCrossRefGoogle Scholar
  178. 178.
    Piret J, Goyette N, Eckenroth BE, Drouot E, Gotte M, Boivin G. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility. J Virol. 2015;89:4636–44.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Piret J, Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis. 2016;29:654–62.PubMedCrossRefGoogle Scholar
  180. 180.
    Piret J, Goyette N, Boivin G. Novel method based on real-time cell analysis for drug susceptibility testing of herpes simplex virus and human cytomegalovirus. J Clin Microbiol. 2016;54:2120–7.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Reyes M, Shaik NS, Graber JM, Nisenbaum R, Wetherall NT, Fukuda K, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med. 2003;163:76–80.PubMedCrossRefGoogle Scholar
  182. 182.
    Rifkin LM, Minkus CL, Pursell K, Jumroendararasame C, Goldstein DA. Utility of leflunomide in the treatment of drug resistant cytomegalovirus retinitis. Ocul Immunol Inflamm. 2017;25:93–6.PubMedCrossRefGoogle Scholar
  183. 183.
    Sacks SL, Shafran SD, Diaz-Mitoma F, Trottier S, Sibbald RG, Hughes A, et al. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother. 1998;42:2996–9.PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis. 1990;161:1078–84.PubMedCrossRefGoogle Scholar
  185. 185.
    Safrin S, Ashley R, Houlihan C, Cusick PS, Mills J. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS. 1991;5:1107–10.PubMedCrossRefGoogle Scholar
  186. 186.
    Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991;115:19–21.PubMedCrossRefGoogle Scholar
  187. 187.
    Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991;325:551–5.PubMedCrossRefGoogle Scholar
  188. 188.
    Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis. 1994;169:193–6.PubMedCrossRefGoogle Scholar
  189. 189.
    Saint-Leger E, Caumes E, Breton G, Douard D, Saiag P, Huraux JM, et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2001;33:2061–7.PubMedCrossRefGoogle Scholar
  190. 190.
    Sarisky RT, Crosson P, Cano R, Quail MR, Nguyen TT, Wittrock RJ, et al. Comparison of methods for identifying resistant herpes simplex virus and measuring antiviral susceptibility. J Clin Virol. 2002;23:191–200.PubMedCrossRefGoogle Scholar
  191. 191.
    Sasadeusz JJ, Sacks SL. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion? J Infect Dis. 1996;174:476–82.PubMedCrossRefGoogle Scholar
  192. 192.
    Sauerbrei A, Taut J, Zell R, Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antivir Res. 2011;90:242–7.PubMedCrossRefGoogle Scholar
  193. 193.
    Sauerbrei A, Liermann K, Bohn K, Henke A, Zell R, Gronowitz S, et al. Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antivir Res. 2012;96:105–7.PubMedCrossRefGoogle Scholar
  194. 194.
    Sauerbrei A, Vodisch S, Bohn K, Schacke M, Gronowitz S. Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTumR assay. J Virol Methods. 2013;188:70–2.PubMedCrossRefGoogle Scholar
  195. 195.
    Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. Eur J Clin Microbiol Infect Dis. 2016;35:723–34.PubMedCrossRefGoogle Scholar
  196. 196.
    Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2016;71:6–16.PubMedCrossRefGoogle Scholar
  197. 197.
    Sawyer MH, Inchauspe G, Biron KK, Waters DJ, Straus SE, Ostrove JM. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus. J Gen Virol. 1988;69:2585–93.PubMedCrossRefGoogle Scholar
  198. 198.
    Schliefer K, Gumbel HO, Rockstroh JK, Spengler U. Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. Clin Infect Dis. 1999;29:684–5.PubMedCrossRefGoogle Scholar
  199. 199.
    Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J Infect Dis. 1999;180:487–90.PubMedCrossRefGoogle Scholar
  200. 200.
    Schnepf N, Boiteau N, Petit F, Alain S, Sanson-Le Pors MJ, Mazeron MC. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR. Antivir Res. 2009;81:64–7.PubMedCrossRefGoogle Scholar
  201. 201.
    Schubert A, Ehlert K, Schuler-Luettmann S, Gentner E, Mertens T, Michel D. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis. 2013;13:330.PubMedPubMedCentralCrossRefGoogle Scholar
  202. 202.
    Sergerie Y, Boivin G. Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses. Antimicrob Agents Chemother. 2006;50:3889–92.PubMedPubMedCentralCrossRefGoogle Scholar
  203. 203.
    Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol. 2006;16:281–7.PubMedCrossRefGoogle Scholar
  204. 204.
    Smith IL, Shinkai M, Freeman WR, Spector SA. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J Infect Dis. 1996;173:1481–4.PubMedCrossRefGoogle Scholar
  205. 205.
    Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997;176:69–77.PubMedCrossRefGoogle Scholar
  206. 206.
    Smith IL, Taskintuna I, Rahhal FM, Powell HC, Ai E, Mueller AJ, et al. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch Ophthalmol. 1998;116:178–85.PubMedGoogle Scholar
  207. 207.
    Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis. 1994;18:570–8.PubMedCrossRefGoogle Scholar
  208. 208.
    SOCA. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. Arch Ophthalmol. 1996;114:23–33.CrossRefGoogle Scholar
  209. 209.
    Springer KL, Chou S, Li S, Giller RH, Quinones R, Shira JE, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol. 2005;43:208–13.PubMedPubMedCentralCrossRefGoogle Scholar
  210. 210.
    Stoelben S, Arns W, Renders L, Hummel J, Muhlfeld A, Stangl M, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int. 2014;27:77–86.PubMedCrossRefGoogle Scholar
  211. 211.
    Stranska R, Schuurman R, Nienhuis E, Goedegebuure IW, Polman M, Weel JF, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol. 2005;32:7–18.PubMedCrossRefGoogle Scholar
  212. 212.
    Strasfeld L, Lee I, Tatarowicz W, Villano S, Chou S. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis. 2010;202:104–8.PubMedCrossRefGoogle Scholar
  213. 213.
    Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature. 1992;358:162–4.PubMedCrossRefGoogle Scholar
  214. 214.
    Swetter SM, Hill EL, Kern ER, Koelle DM, Posavad CM, Lawrence W, et al. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis. 1998;177:543–50.PubMedCrossRefGoogle Scholar
  215. 215.
    Swierkosz EM, Hodinka RL, Moore BM, Sacks S, Scholl DR, Wright DK. Antiviral susceptibility testing: Herpes simplex virus by plaque reduction assay; approved standard. Wayne, PA: Clinical and Laboratory Standards Institute; 2004. p. 1–39.Google Scholar
  216. 216.
    Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol. 1993;67:1024–33.PubMedPubMedCentralGoogle Scholar
  217. 217.
    Tatarowicz WA, Lurain NS, Thompson KD. In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus. J Virol Methods. 1991;35:207–15.PubMedCrossRefGoogle Scholar
  218. 218.
    Tchesnokov EP, Gilbert C, Boivin G, Gotte M. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. J Virol. 2006;80:1440–50.PubMedPubMedCentralCrossRefGoogle Scholar
  219. 219.
    Telenti A, Smith TF. Screening with a shell vial assay for antiviral activity against cytomegalovirus. Diagn Microbiol Infect Dis. 1989;12:5–8.PubMedCrossRefGoogle Scholar
  220. 220.
    Topalis D, Gillemot S, Snoeck R, Andrei G. Distribution and effects of amino acid changes in drug-resistant alpha and beta herpesviruses DNA polymerase. Nucleic Acids Res. 2016;44:9530–54.PubMedPubMedCentralGoogle Scholar
  221. 221.
    Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012;84:1224–32.PubMedCrossRefGoogle Scholar
  222. 222.
    van der Beek MT, Vermont CL, Bredius RG, Marijt EW, van der Blij-de Brouwer CS, Kroes AC, et al. Persistence and antiviral resistance of VZV in hematological patients. Clin Infect Dis. 2013;56:335–43.PubMedCrossRefGoogle Scholar
  223. 223.
    van Velzen M, van Loenen FB, Meesters RJ, de Graaf M, Remeijer L, Luider TM, et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis. 2012;205:1539–43.PubMedCrossRefGoogle Scholar
  224. 224.
    van Velzen M, Missotten T, van Loenen FB, Meesters RJ, Luider TM, Baarsma GS, et al. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. J Clin Virol. 2013;57:215–21.PubMedCrossRefGoogle Scholar
  225. 225.
    Vere Hodge RA, Field HJ. Antiviral agents for herpes simplex virus. Adv Pharmacol. 2013;67:1–38.PubMedCrossRefGoogle Scholar
  226. 226.
    Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis. 1998;178:S55–7.PubMedCrossRefGoogle Scholar
  227. 227.
    Visse B, Huraux JM, Fillet AM. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol. 1999;59:84–90.PubMedCrossRefGoogle Scholar
  228. 228.
    Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med. 1982;96:265–9.PubMedCrossRefGoogle Scholar
  229. 229.
    Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis. 1983;148:1077–82.PubMedCrossRefGoogle Scholar
  230. 230.
    Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370:201–10.PubMedCrossRefGoogle Scholar
  231. 231.
    Weinberg A, Jabs DA, Chou S, Martin BK, Lurain NS, Forman MS, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187:777–84.PubMedCrossRefGoogle Scholar
  232. 232.
    Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med. 1992;327:782–9.PubMedCrossRefGoogle Scholar
  233. 233.
    Williamson EC, Millar MR, Steward CG, Cornish JM, Foot AB, Oakhill A, et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol. 1999;104:560–8.PubMedCrossRefGoogle Scholar
  234. 234.
    Wolf DG, Lee DJ, Spector SA. Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother. 1995;39:2552–4.PubMedPubMedCentralCrossRefGoogle Scholar
  235. 235.
    Wolf DG, Smith IL, Lee DJ, Freeman WR, Flores-Aguilar M, Spector SA. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest. 1995;95:257–63.PubMedPubMedCentralCrossRefGoogle Scholar
  236. 236.
    Wolf DG, Yaniv I, Honigman A, Kassis I, Schonfeld T, Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis. 1998;178:535–8.PubMedCrossRefGoogle Scholar
  237. 237.
    Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood. 2003;101:463–5.PubMedCrossRefGoogle Scholar
  238. 238.
    Zahn KE, Tchesnokov EP, Gotte M, Doublie S. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. J Biol Chem. 2011;286:25246–55.PubMedPubMedCentralCrossRefGoogle Scholar
  239. 239.
    Ziyaeyan M, Alborzi A, Japoni A, Kadivar M, Davarpanah MA, Pourabbas B, et al. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. Int J Dermatol. 2007;46:1263–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departments of Pathology and Laboratory MedicineUniversity of CaliforniaSan FranciscoUSA
  2. 2.Research Center in Infectious Diseases of the CHU of Quebec- Laval UniversityQuebec CityCanada

Personalised recommendations